Nimbus Discovery Presents Compelling Preclinical Proof of Concept Data on Novel ACC Allosteric Inhibitor ND-630
6/24/2013 11:23:29 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nimbus Discovery LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible drug targets, presented preclinical data today that show that the company’s Acetyl CoA Carboxylase (ACC) allosteric inhibitor, ND-630, improves insulin sensitivity; produces a dose dependent reduction in whole body fat markers; and decreases triglycerides, fatty acids and cholesterol in diet-induced models of obesity. The data were unveiled at the American Diabetes Association's 73rd Scientific Sessions in Chicago, Ill., in poster 636-P/0636 entitled, “Acetyl-CoA carboxylase inhibition by ND-630 inhibits fatty acid synthesis, stimulates fatty acid oxidation, reduces body weight, improves insulin sensitivity, and modulates dyslipidemia in rats.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by